- Assistant Professor, Department of Molecular, Cellular and Developmental Biology, Yale School of Medicine, Yale University
Dr. Gregory Craven is an Assistant Professor in the Department of Molecular, Cellular and Developmental Biology at Yale University, where his laboratory is part of the Institute of Biomolecular Design and Discovery. His research focuses on the design of small molecule inhibitors and chemical tools to probe and perturb dysregulated signaling pathways.
Dr. Craven earned a first-class degree in Chemistry from the University of Oxford and completed his PhD at Imperial College London, where his doctoral work focused on fragment-based drug discovery and cysteine targeting. He subsequently conducted postdoctoral research at the University of California, San Francisco, developing lysine-targeted covalent inhibitors and chemoproteomic methods. This work led to the discovery of the first mutant-selective inhibitor of AKT1(E17K), a common driver of breast cancer.
At Yale, Dr. Craven’s lab integrates small-molecule design and synthesis, proteomic mass spectrometry, structural biology, and biochemistry. For the Colton Consortium, his group is applying this ligand discovery platform to Activated PI3K-delta Syndrome (APDS), with the goal of developing mutant-selective chemical tools and therapeutic leads that restore dysregulated signaling while sparing normal enzyme function.